Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 18472368)

1.

Does treatment duration affect outcome after radiotherapy for prostate cancer?

D'Ambrosio DJ, Li T, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1402-7. doi: 10.1016/j.ijrobp.2008.03.011. Epub 2008 May 9.

2.

Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.

Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):125-30. doi: 10.1016/j.ijrobp.2009.04.074. Epub 2009 Aug 19.

3.

Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.

Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):19-24.

PMID:
14697416
4.
5.

What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1003-10.

PMID:
15752879
6.

A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.

Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):380-5.

PMID:
15145151
7.

PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.

Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50. Epub 2005 Sep 29.

PMID:
16198506
8.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
9.

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL.

J Clin Oncol. 2010 Jun 1;28(16):2653-9. doi: 10.1200/JCO.2009.27.3003. Epub 2010 Apr 26.

10.

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. doi: 10.1016/j.ijrobp.2008.10.071. Epub 2009 Mar 14.

PMID:
19289266
11.
12.

External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.

Pollack A, Smith LG, von Eschenbach AC.

Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12.

PMID:
10974469
13.

A systematic overview of radiation therapy effects in prostate cancer.

Nilsson S, Norlén BJ, Widmark A.

Acta Oncol. 2004;43(4):316-81. Review.

PMID:
15303499
14.

PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.

Ko EC, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. doi: 10.1016/j.ijrobp.2011.07.009. Epub 2011 Oct 8.

PMID:
21985944
15.
16.

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):704-11.

PMID:
11849793
17.

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

Hanlon AL, Diratzouian H, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303.

PMID:
12023133
18.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9.

PMID:
15667961
19.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

20.

Impact of race on biochemical disease recurrence after prostate brachytherapy.

Yamoah K, Stone N, Stock R.

Cancer. 2011 Dec 15;117(24):5589-600. doi: 10.1002/cncr.26183. Epub 2011 Jun 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk